Update on Drugs Used to Treat Endocrine Diseases in Small Animals

Veterinary Clinics of North America - Small Animal Practice

Volumn 36, Issue 5, 2006, Pages 1087-1105

  Behrend, Ellen N ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBIMAZOLE; GESTAGEN; GROWTH HORMONE; INSULIN; INSULIN GLARGINE; INSULIN ZINC SUSPENSION; IODINE 131; IOPODIC ACID; ISOPHANE INSULIN; KETOCONAZOLE; MEDROXYPROGESTERONE ACETATE; MITOTANE; ORAL ANTIDIABETIC AGENT; PROLIGESTONE; SELEGILINE; THIAMAZOLE; TRILOSTANE; VETSULIN;

DIABETES MELLITUS; DIET THERAPY; DRUG METABOLISM; ENDOCRINE DISEASE; GLUCOSE BLOOD LEVEL; GROWTH HORMONE DEFICIENCY; HYPERADRENOCORTICISM; HYPERTHYROIDISM; NONHUMAN; PITUITARY DWARFISM; PRACTICE GUIDELINE; REVIEW;

ADRENOCORTICAL HYPERFUNCTION; ANIMALS; ANTITHYROID AGENTS; CAT DISEASES; CATS; DIABETES MELLITUS; DIHYDROTESTOSTERONE; DOG DISEASES; DOGS; ENZYME INHIBITORS; HYPERTHYROIDISM; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; METHIMAZOLE;

ANIMALIA;

EID: 33748568460     PISSN: 01955616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cvsm.2006.05.007     Document Type: Review

References (70)

1. 131I. Vet Radiol Ultrasound 38 (1997) 231-238
2. Rogers K.S., Burkholder W.J., Slater M.R., et al. Development and predictors for renal disease and clinical outcomes in hyperthyroid cats treated with 131-I. [abstract]. J Vet Intern Med 14 (2000) 343
3. Peterson M.E., Kintzer P.P., and Hurvitz A.I. Methimazole treatment of 262 cats with hyperthyroidism. J Vet Intern Med 2 (1988) 150-157
4. Shelton G.D., Joseph R., Richter K., et al. Acquired myasthenia gravis in hyperthyroid cats on tapazole therapy. [abstract]. J Vet Intern Med 11 (1997) 120
5. Graves T.K. Complications of treatment and concurrent illness associated with hyperthyroidism in cats. In: Bonagura J.D. (Ed). Kirk's current veterinary therapy XII: small animal practice (1996), WB Saunders, Philadelphia 369-372
6. Trepanier L.A., Hoffman S.B., Kroll M., et al. Efficacy and safety of once versus twice daily administration of methimazole in cats with hyperthyroidism. J Am Vet Med Assoc 222 (2003) 954-958
7. Feldman E.C., and Nelson R.W. Feline hyperthyroidism (thyrotoxicosis). In: Feldman E.C., and Nelson R.W. (Eds). Canine and feline endocrinology and reproduction (2004), WB Saunders, St. Louis (MO) 152-218
8. Hoffman S.B., Yoder A.R., and Trepanier L.A. Bioavailability of transdermal methimazole in pluronic lecithin organogel (PLO) in healthy cats. J Vet Pharmacol Ther 25 (2002) 189-193
9. Hoffman G., Marks S.L., Taboada J., et al. Transdermal methimazole treatment in cats with hyperthyroidism. J Feline Med Surg 5 (2003) 77-82
10. Sartor L.L., Trepanier L.A., Kroll M.M., et al. Clinical efficacy of transdermal methimazole in cats with hyperthyroidism. J Vet Intern Med 18 (2004) 651-655
11. Nieckarz J.A., and Daniel G.B. The effect of methimazole on thyroid uptake of pertechnetate and radioiodine in normal cats. Vet Radiol Ultrasound 42 (2001) 448-457
12. Nelson R.W., Duesberg C.A., Ford S.L., et al. Effect of dietary insoluble fiber on control of glycemia in dogs with naturally acquired diabetes mellitus. J Am Vet Med Assoc 212 (1998) 380-386
13. Kimmel S.E., Michel K.E., Hess R.S., et al. Effects of insoluble and soluble dietary fiber on glycemic control in dogs with naturally occurring insulin-dependent diabetes mellitus. J Am Vet Med Assoc 216 (2000) 1076-1082
14. Fleeman L.M., Rand J.S., and Markwell P.J. Diets with high fiber and moderate starch are not advantageous for dogs with stabilized diabetes compared to a commercial diet with moderate fiber and low starch. [abstract]. J Vet Intern Med 17 (2003) 433
15. Nelson R.W., Scott-Moncrieff C., Feldman E.C., et al. Effect of dietary insoluble fiber on control of glycemia in cats with naturally acquired diabetes mellitus. J Am Vet Med Assoc 216 (2000) 1082-1088
16. Mazzaferro E.M., Greco D.S., Turner A.S., et al. Treatment of feline diabetes mellitus using an α-glucosidase inhibitor and a low-carbohydrate diet. J Feline Med Surg 5 (2003) 183-189
17. Frank G., Anderson W., Pazak H., et al. Use of a high-protein diet in the management of feline diabetes mellitus. Vet Ther 2 (2001) 238-246
18. Feldman E.C., and Nelson R.W. Canine diabetes mellitus. In: Feldman E.C., and Nelson R.W. (Eds). Canine and feline endocrinology and reproduction (2004), WB Saunders, St. Louis (MO) 486-538
19. Feldman E.C., and Nelson R.W. Feline diabetes mellitus. In: Feldman E.C., and Nelson R.W. (Eds). Canine and feline endocrinology and reproduction (2004), WB Saunders, St. Louis (MO) 539-579
20. Monroe W.E., Laxton D., Fallin E.A., et al. Efficacy and safety of a purified porcine insulin zinc suspension for managing diabetes mellitus in dogs. J Vet Intern Med 19 (2005) 675-682
21. Fleeman L.M., and Rand J.S. Management of canine diabetes. Vet Clin North Am Small Anim Pract 31 (2001) 855-880
22. Hess R.S., and Ward C.R. Effect of insulin dosage on glycemic response in dogs with diabetes mellitus: 221 cases (1993-1998). J Am Vet Med Assoc 216 (2000) 217-221
23. Nelson R.W., Lynn R.C., Wagner-Mann C.C., et al. Efficacy of protamine zinc insulin for treatment of diabetes mellitus in cats. J Am Vet Med Assoc 218 (2001) 38-42
24. Rand JS, Marshall RD. Insulin glargine and the treatment of feline diabetes mellitus. In: Proceedings of the 22nd Annual American College of Veterinary Internal Medicine Forum, Minneapolis, MN, 2004. p. 584-6.
25. Marshall R.D., and Rand J.S. Insulin glargine and a high protein-low carbohydrate diet are associated with high remission rates in newly diagnosed diabetic cats. [abstract]. J Vet Intern Med 18 (2004) 401
26. Martin G.J., and Rand J.S. Pharmacology of a 40 IU/ml porcine lente insulin preparation in diabetic cats: findings during the first week and after 5 or 9 weeks of therapy. J Feline Med Surg 3 (2001) 23-30
27. Rand J.S. Management of feline diabetes. Aust Vet Pract 27 (1997) 68-76
28. Reusch CE. Monitoring and treatment of the diabetic cat. In: Proceedings of the European College of Veterinary Internal Medicine-Companion Animal 15th Annual Congress, Glasgow, Scotland, 2005. p. 125-7.
29. Rand JS. Understanding feline diabetes. In: Proceedings of the 14th Ann American College of Veterinary Internal Medicine Forum, San Antonio, TX, 1996. p. 82-3.
30. Nelson R.W. Disorders of the endocrine pancreas. In: Nelson R.W., and Couto C.G. (Eds). Essentials of small animal internal medicine (1998), Mosby Year Book, Philadelphia 734-774
31. Fleeman L.M., and Rand J.S. Evaluation of day-to-day variability of serial blood glucose concentration curves in diabetic dogs. J Am Vet Med Assoc 222 (2003) 317-321
32. Ristic J.M.E., Herrtage M.E., Walti-Lauger S.M.M., et al. Evaluation of a continuous glucose monitoring system in cats with diabetes mellitus. J Feline Med Surg 7 (2005) 153-162
33. Rand JS, Marshall RD. Update on insulin glargine use in diabetic cats. In: Proceedings of the 23rd Annual American College of Veterinary Internal Medicine Forum, Baltimore, MD, 2005. p. 483-4.
34. Rand J.S. Pathogenesis of feline diabetes. In: Reinhart G.A., and Carey D.P. (Eds). Recent advances in canine and feline nutrition: 1998 Iams Nutrition Symposium Proceedings (1998), Orange Frazer Press, Wilmington (OH) 83-95
35. Nelson R.W., Griffey S.M., Feldman E.C., et al. Transient clinical diabetes mellitus in cats: 10 cases (1989-1991). J Vet Intern Med 13 (1999) 28-35
36. Nelson R.W., Feldman E.C., Ford S.L., et al. Effect of an orally administered sulfonylurea, glipizide, for treatment of diabetes mellitus in cats. J Am Vet Med Assoc 203 (1993) 821-827
37. Feldman E.C., Nelson R.W., and Feldman M.S. Intensive 50-week evaluation of glipizide administration in 50 cats with previously untreated diabetes mellitus. J Am Vet Med Assoc 210 (1997) 772-777
38. Reusch C.E., Wess G., and Casella M. Home monitoring of blood glucose concentration in the management of diabetes mellitus. Compend Contin Educ Pract Vet 23 (2001) 544-556
39. Casella M., Wess G., and Reusch C.E. Measurement of capillary blood glucose concentrations by pet owners: a new tool in the management of diabetes mellitus. J Am Anim Hosp Assoc 38 (2002) 239-245
40. Maele V.D., and Daminet R. Retrospective study of owners' perceptions on home monitoring of blood glucose in diabetic dogs and cats. Can Vet J 46 (2005) 718-723
41. Casella M., Wess G., Hassig M., et al. Home monitoring of blood glucose concentration by owners of diabetic dogs. J Small Anim Pract 44 (2003) 298-305
42. Casella M., Hassig M., and Reusch C.E. Home-monitoring of blood glucose in cats with diabetes mellitus: evaluation over a 4-month period. J Feline Med Surg 7 (2005) 163-171
43. Wiedmeyer C.E., Johnson P.J., Cohn L.A., et al. Evaluation of a continuous glucose monitoring system for use in dogs, cats, and horses. J Am Vet Med Assoc 223 (2003) 987-992
44. Davison L.J., Slater L.A., Herrtage M.E., et al. Evaluation of continuous glucose monitoring system in diabetic dogs. J Small Anim Pract 44 (2003) 435-442
45. Elliott D.A., Nelson R.W., Feldman E.C., et al. Glycosylated hemoglobin concentrations in the blood of healthy dogs and dogs with naturally developing diabetes mellitus, pancreatic B-cell neoplasia, hyperadrenocorticism, and anemia. J Am Vet Med Assoc 211 6 (1997) 723-727
46. Elliott D.A., Nelson R.W., Reusch C.E., et al. Comparison of serum fructosamine and blood glycosylated hemoglobin concentrations for assessment of glycemic control in cats with diabetes mellitus. J Am Vet Med Assoc 214 (1999) 1794-1798
47. Plier M.L., Grindem C.B., MacWilliams P.S., et al. Serum fructosamine concentration in nondiabetic and diabetic cats. Vet Clin Pathol 27 (1998) 34-39
48. Elliott D.A., Nelson R.W., and Feldman E.C. Glycosylated hemoglobin concentration for assessment of glycemic control in diabetic cats. J Vet Intern Med 11 (1997) 161-165
49. Briggs C.E., Nelson R.W., Feldman E.C., et al. Reliability of history and physical examination findings for assessing control of glycemia in dogs with diabetes mellitus: 53 cases (1995-1998). J Am Vet Med Assoc 217 (2000) 48-53
50. Meij B., Voorhout G., and Rijnberk A. Progress in transsphenoidal hypophysectomy for treatment of pituitary-dependent hyperadrenocorticism in dogs and cats. Molec Cell Endocrin 197 (2002) 89-96
51. Feldman E.C., and Nelson R.W. Canine hyperadrenocorticism (Cushing's syndrome). In: Feldman E.C., and Nelson R.W. (Eds). Canine and feline endocrinology and reproduction (2004), WB Saunders, St. Louis (MO) 252-357
52. Behrend E.N., and Kemppainen R.J. Medical therapy of canine Cushing's syndrome. Compend Contin Educ Pract Vet 20 6 (1998) 679-697
53. Sonino N., Boscaro M., and Paoletta A. Ketoconazole treatment in Cushing's syndrome: experience in 34 patients. Clin Endocrinol (Oxf) 35 (1991) 347-352
54. West J.R. Ketoconazole in Cushing's syndrome. Ann Pharmacol 21 (1987) 972-973
55. Behrend E.N., Kemppainen R.J., Clark T.P., et al. Treatment of hyperadrenocorticism in dogs: a survey of internists and dermatologists. J Am Vet Med Assoc 215 (1999) 938-943
56. Reusch C., Steffen T., and Hoerauf A. The efficacy of L-deprenyl in dogs with pituitary-dependent hyperadrenocorticism. J Vet Intern Med 13 (1999) 291-301
57. Braddock J.A., Church D.B., Robertson I.D., et al. Inefficacy of selegiline in treatment of canine pituitary-dependent hyperadrenocorticism. Aust Vet J 82 (2004) 272-277
58. Neiger R., Ramsey I.K., O'Conner J., et al. Trilostane treatment of 78 dogs with pituitary-dependent hyperadrenocorticism. Vet Rec 150 (2002) 799-804
59. Ruckstuhl N.S., Nett C.S., and Reusch C. Results of clinical examinations, laboratory tests, and ultrasonography in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane. Am J Vet Res 63 (2002) 506-512
60. Braddock J.A., Church D.B., Robertson I.D., et al. Trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism. Aust Vet J 81 (2003) 600-607
61. Barker E.N., Campbell S., Tebb A.J., et al. A comparison of the survival times of dogs treated with mitotane or trilostane for pituitary-dependent hyperadrenocorticism. J Vet Intern Med 19 (2005) 810-815
62. Neiger R, Ramsey IK. Trilostane therapy of canine hyperadrenocorticism. In: Proceedings of the 20th Annual American College of Veterinary Internal Medicine Forum, Dallas, TX, 2002. p. 544-6.
63. Neiger R. Hyperadrenocorticism: the animal perspective-comparative efficacy and safety of trilostane. In: Proceedings of the Annual Veterinary Medical Forum, Minneapolis, MN, 2004. p. 699-701.
64. Chapman P.S., Kelly D.F., Archer J., et al. Adrenal necrosis in a dog receiving trilostane for the treatment of hyperadrenocorticism. J Small Anim Pract 45 (2004) 307-310
65. Eastwood J.M., Elwood C.M., and Hurley K.J. Trilostane treatment of a dog with functional adrenocortical neoplasia. J Small Anim Pract 44 (2003) 126-131
66. Mantis P., Lamb C.R., Witt A., et al. Changes in ultrasonographic appearance of adrenal glands in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane. Vet Radiol Ultrasound 44 (2003) 682-685
67. van Herpen H., Rijnberk A., and Mol J.A. Production of antibodies to biosynthetic human growth hormone in the dog. Vet Rec 134 (1994) 171
68. Feldman E.C., and Nelson R.W. Disorders of growth hormone. In: Feldman E.C., and Nelson R.W. (Eds). Canine and feline endocrinology and reproduction (2004), WB Saunders, St. Louis (MO) 45-84
69. Kooistra H.S., Voorhout G., Selman P.J., et al. Progestin-induced growth hormone (GH) production in the treatment of dogs with congenital GH deficiency. Domest Anim Endocrinol 15 (1998) 93-102
70. Knottenbelt C.M., and Herrtage M.E. Use of proligestone in the management of three German shepherd dogs with pituitary dwarfism. J Small Anim Pract 43 (2002) 164-170